1. A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
- Author
-
Haichen Lv, Mei-Yun Fang, Yunlong Xia, Si-Xun Jia, Liang-Liang Ma, and Ying Liu
- Subjects
Melphalan ,medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Short Communication ,030204 cardiovascular system & hematology ,Autologous stem cell transplantation ,lcsh:RC254-282 ,Conditioning regimen ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,immune system diseases ,Multiple myeloma ,hemic and lymphatic diseases ,Medicine ,cardiovascular diseases ,Sinus (anatomy) ,business.industry ,Sinus arrest ,High dose melphalan ,Atrial fibrillation ,General Medicine ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Surgery ,medicine.anatomical_structure ,surgical procedures, operative ,lcsh:RC666-701 ,030220 oncology & carcinogenesis ,cardiovascular system ,Supraventricular tachycardia ,business ,Arrhythmia ,medicine.drug - Abstract
High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventricular tachycardia and atrial fibrillation. Here, we report a rare case of a 58 year old female with multiple myeloma, who developed sinus arrest after autologous stem cell transplantation using high dose melphalan as a conditioning regimen. It was severe and rare, therefore, monitoring for cardiac toxicity in patients receiving high-dose melphalan is mandatory.
- Published
- 2020